Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation

NCT00795548 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndrome
Acute Myeloid Leukemia

Interventions

DRUG: 5-Azacitidine

Sponsor

Heinrich-Heine University, Duesseldorf